1. Home
  2. WULF vs COGT Comparison

WULF vs COGT Comparison

Compare WULF & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TeraWulf Inc.

WULF

TeraWulf Inc.

HOLD

Current Price

$16.29

Market Cap

6.8B

Sector

Technology

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$36.37

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WULF
COGT
Founded
1952
2014
Country
United States
United States
Employees
12
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
6.5B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
WULF
COGT
Price
$16.29
$36.37
Analyst Decision
Strong Buy
Buy
Analyst Count
13
14
Target Price
$17.58
$32.08
AVG Volume (30 Days)
37.1M
1.8M
Earning Date
02-26-2026
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$167,604,000.00
N/A
Revenue This Year
$29.95
N/A
Revenue Next Year
$117.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.58
N/A
52 Week Low
$2.06
$3.72
52 Week High
$17.70
$43.73

Technical Indicators

Market Signals
Indicator
WULF
COGT
Relative Strength Index (RSI) 59.24 45.95
Support Level $15.36 $35.50
Resistance Level $17.70 $38.19
Average True Range (ATR) 1.69 1.72
MACD 0.24 -0.16
Stochastic Oscillator 76.36 20.96

Price Performance

Historical Comparison
WULF
COGT

About WULF TeraWulf Inc.

TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: